A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)
Phase 2
Completed
- Conditions
- Smoking
- Registration Number
- NCT00109135
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to evaluate the safety and tolerability of an investigational drug that may help individuals to stop smoking.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Smoking greater than/equal to 10 cigarettes/day for at least 1 year
- Laboratory tests that meet the criteria of the study
- In overall good health as determined by the investigator
Exclusion Criteria
- Psychiatric diagnoses
- Certain cancers
- Patients who use nicotine replacement therapy
- Patients on a diet regimen
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Quitting smoking after 8 weeks of treatment by measuring lab values and expired breath CO levels after 8 weeks of treatment
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does MK0364 target to aid smoking cessation in chronic smokers?
How does MK0364's efficacy compare to standard-of-care treatments like varenicline or nicotine replacement therapy?
Are there specific biomarkers that predict response to MK0364 in nicotine-dependent individuals?
What are the potential adverse events associated with MK0364 and how are they managed in clinical trials?
What related compounds or combination therapies are being explored by Merck Sharp & Dohme LLC for smoking cessation alongside MK0364?